Integrative transcriptome analysis of liver cancer profiles identifies upstream regulators and clinical significance of ACSM3 gene expression
- 452 Downloads
Hepatocellular carcinoma (HCC) is one of the most common human malignancies. It has frequently been associated with metabolic perturbations and liver damages. Various members of the family of acyl-CoA synthetases are known to be involved in the production of bioactive fatty acids, and altered expression of its encoding genes has been found to be involved in metabolic perturbations. For the development of novel diagnostic and therapeutic HCC options, a fundamental understanding of the mechanisms associated with the deregulation of candidate genes involved in metabolic perturbation is required.
A meta-analysis of multiple HCC mRNA profiles was performed to identify consistently deregulated genes. Expression of the acyl-CoA synthetase medium chain family member 3 (ACSM3) gene was subsequently assessed in different HCC tumor stages and correlated with various clinicopathological features. Transcription regulation, survival and pathway-associated features of the ACSM3 gene were investigated using integrative functional genomic and molecular cell biological methods.
We found that expression of the ACSM3 gene was significantly reduced in HCC tissues and was frequently downregulated in patients exhibiting high alpha-fetoprotein (AFP) levels, high alanine aminotransferase (ALT) levels, multiple nodules and large tumors. Loss of ACSM3 expression was found to correlate with advanced HCC stages and a poor survival. In addition, HNF4α was found to positively regulate the expression of the ACSM3 gene, while PPARγ was found to transcriptionally repress it. Downregulation of ACSM3 expression was perceived upon activation of the TGFβ, WNT, AKT and MYC signalling pathways. In addition, we found that ACSM3 expression correlates with fatty acid oxidation in HCC.
Our data provide evidence for a differential expression and regulation of the ACSM3 gene in HCC, and may lay a foundation for therapeutically targeting fatty acid metabolism in these tumors.
KeywordsHepatocellular carcinoma Meta-analysis Acyl-CoA synthetases ACSM3 HNF4α PPARγ Fatty acid oxidation
This study was supported by grants from the Department of Atomic Energy (DAE), Government of India (Grant No.6/6/2008/R&D-II-230R) and the Department of Biotechnology (DBT), Government of India (MKU-DBT–IPLS programme, No.BT/PR 14553/INF/22/124/2010). Instrumentation support from UGC-CEGS, DBT-IPLS, UGC-NRCBS, UGC-CAS, and the DST-PURSE programme-supported central facilities of SBS, MKU are greatly acknowledged.
Compliance with ethical standards
Conflict of interest
Conflict of Interest for all authors – None.
- 4.J.M. Llovet, J. Bustamante, A. Castells, R. Vilana, C. Ayuso Mdel, M. Sala, C. Bru, J. Rodes, J. Bruix, Natural history of untreated nonsurgical hepatocellular carcinoma: Rationale for the design and evaluation of therapeutic trials. Hepatology 29, 62–67 (1999). doi: 10.1002/hep.510290145 CrossRefPubMedGoogle Scholar
- 5.K.T. Padhya, J.A. Marrero, A.G. Singal, J.K. Choi, J.Y. Choi, D.G. Kim, D.W. Choi, B.Y. Kim, K.H. Lee, Y.I. Yeom, H.S. Yoo, O.J. Yoo, S. Kim, Recent advances in the treatment of hepatocellular carcinoma. Curr Opin Gastroenterol 29, 285–292 (2013). doi: 10.1097/MOG.0b013e32835ff1cf CrossRefPubMedGoogle Scholar
- 7.S.K. Chan, O.L. Griffith, I.T. Tai, S.J. Jones, R. Elkon, C. Linhart, R. Sharan, R. Shamir, Y. Shiloh, Meta-analysis of colorectal cancer gene expression profiling studies identifies consistently reported candidate biomarkers. Cancer Epidemiol Biomark Prev 17, 543–552 (2008). doi: 10.1158/1055-9965.EPI-07-2615 CrossRefGoogle Scholar
- 11.E. Currie, A. Schulze, R. Zechner, T.C. Walther, R.V. Farese Jr., Cellular fatty acid metabolism and cancer. Cell Metab 18, 153–161 (2013). doi: 10.1016/j.cmet.2013.05.017
- 13.H. Cai, H. Chen, T. Yi, C.M. Daimon, J.P. Boyle, C. Peers, S. Maudsley, B. Martin, VennPlex--a novel Venn diagram program for comparing and visualizing datasets with differentially regulated datapoints. PLoS One 8, e53388 (2013). doi: 10.1371/journal.pone.0053388 CrossRefPubMedPubMedCentralGoogle Scholar
- 17.A. Subramanian, P. Tamayo, V.K. Mootha, S. Mukherjee, B.L. Ebert, M.A. Gillette, A. Paulovich, S.L. Pomeroy, T.R. Golub, E.S. Lander, J.P. Mesirov, Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci U S A 102, 15545–15550 (2005). doi: 10.1073/pnas.0506580102 CrossRefPubMedPubMedCentralGoogle Scholar
- 18.K. Kandasamy, S.S. Mohan, R. Raju, S. Keerthikumar, G.S. Kumar, A.K. Venugopal, D. Telikicherla, J.D. Navarro, S. Mathivanan, C. Pecquet, S.K. Gollapudi, S.G. Tattikota, S. Mohan, H. Padhukasahasram, Y. Subbannayya, R. Goel, H.K. Jacob, J. Zhong, R. Sekhar, V. Nanjappa, L. Balakrishnan, R. Subbaiah, Y.L. Ramachandra, B.A. Rahiman, T.S. Prasad, J.X. Lin, J.C. Houtman, S. Desiderio, J.C. Renauld, S.N. Constantinescu, O. Ohara, T. Hirano, M. Kubo, S. Singh, P. Khatri, S. Draghici, G.D. Bader, C. Sander, W.J. Leonard, A. Pandey, NetPath: a public resource of curated signal transduction pathways. Genome Biol 11, R3 (2010). doi: 10.1186/gb-2010-11-1-r3 CrossRefPubMedPubMedCentralGoogle Scholar
- 19.M. Muthuswami, V. Ramesh, S. Banerjee, S. Viveka Thangaraj, J. Periasamy, D. Bhaskar Rao, G.D. Barnabas, S. Raghavan, K. Ganesan, B.W. Dyer, F.A. Ferrer, D.K. Klinedinst and R. Rodriguez. Breast tumors with elevated expression of 1q candidate genes confer poor clinical outcome and sensitivity to Ras/PI3K inhibition. e77553 (2013). doi: 10.1371/journal.pone.0077553
- 23.I. Boomgaarden, C. Vock, M. Klapper, F. Doring, Y. Hoshida, S.M. Nijman, M. Kobayashi, J.A. Chan, J.P. Brunet, D.Y. Chiang, A. Villanueva, P. Newell, K. Ikeda, M. Hashimoto, G. Watanabe, S. Gabriel, S.L. Friedman, H. Kumada, J.M. Llovet, T.R. Golub, J.W. Kim, Q. Ye, M. Forgues, Y. Chen, A. Budhu, J. Sime, L.J. Hofseth, R. Kaul, X.W. Wang, Comparative analyses of disease risk genes belonging to the acyl-CoA synthetase medium-chain (ACSM) family in human liver and cell lines. Biochem Genet 47, 739–748 (2009). doi: 10.1007/s10528–009-9273-z CrossRefPubMedGoogle Scholar
- 26.J.M. Seargent, E.A. Yates, J.H. Gill, GW9662, a potent antagonist of PPARgamma, inhibits growth of breast tumour cells and promotes the anticancer effects of the PPARgamma agonist rosiglitazone, independently of PPARgamma activation. Br J Pharmacol 143, 933–937 (2004). doi: 10.1038/sj.bjp.0705973 CrossRefPubMedPubMedCentralGoogle Scholar
- 28.C.P. Martinez-Jimenez, I. Kyrmizi, P. Cardot, F.J. Gonzalez, I. Talianidis, S. Yu, K. Matsusue, P. Kashireddy, W.Q. Cao, V. Yeldandi, A.V. Yeldandi, M.S. Rao, J.K. Reddy, Hepatocyte nuclear factor 4alpha coordinates a transcription factor network regulating hepatic fatty acid metabolism. Mol Cell Biol 30, 565–577 (2010). doi: 10.1128/MCB.00927-09 CrossRefPubMedGoogle Scholar
- 29.S. Yu, K. Matsusue, P. Kashireddy, W.Q. Cao, V. Yeldandi, A.V. Yeldandi, M.S. Rao, F.J. Gonzalez, J.K. Reddy, Adipocyte-specific gene expression and adipogenic steatosis in the mouse liver due to peroxisome proliferator-activated receptor gamma1 (PPARgamma1) overexpression. J Biol Chem 278, 498–505 (2003). doi: 10.1074/jbc.M210062200 CrossRefPubMedGoogle Scholar
- 31.Y. Hoshida, S.M. Nijman, M. Kobayashi, J.A. Chan, J.P. Brunet, D.Y. Chiang, A. Villanueva, P. Newell, K. Ikeda, M. Hashimoto, G. Watanabe, S. Gabriel, S.L. Friedman, H. Kumada, J.M. Llovet, T.R. Golub, N. Iwai, T. Mannami, H. Tomoike, K. Ono, Y. Iwanaga, Integrative transcriptome analysis reveals common molecular subclasses of human hepatocellular carcinoma. Cancer Res 69, 7385–7392 (2009). doi: 10.1158/0008-5472.CAN-09-1089 CrossRefPubMedPubMedCentralGoogle Scholar
- 34.A. Budhu, M. Forgues, Q.H. Ye, H.L. Jia, P. He, K.A. Zanetti, U.S. Kammula, Y. Chen, L.X. Qin, Z.Y. Tang, X.W. Wang, Prediction of venous metastases, recurrence, and prognosis in hepatocellular carcinoma based on a unique immune response signature of the liver microenvironment. Cancer Cell 10, 99–111 (2006). doi: 10.1016/j.ccr.2006.06.016 CrossRefPubMedGoogle Scholar
- 35.H.L. Jia, Q.H. Ye, L.X. Qin, A. Budhu, M. Forgues, Y. Chen, Y.K. Liu, H.C. Sun, L. Wang, H.Z. Lu, F. Shen, Z.Y. Tang, X.W. Wang, Gene expression profiling reveals potential biomarkers of human hepatocellular carcinoma. Clin Cancer Res 13, 1133–1139 (2007). doi: 10.1158/1078-0432.CCR-06-1025 CrossRefPubMedGoogle Scholar
- 36.Q.H. Ye, L.X. Qin, M. Forgues, P. He, J.W. Kim, A.C. Peng, R. Simon, Y. Li, A.I. Robles, Y. Chen, Z.C. Ma, Z.Q. Wu, S.L. Ye, Y.K. Liu, Z.Y. Tang, X.W. Wang, Predicting hepatitis B virus-positive metastatic hepatocellular carcinomas using gene expression profiling and supervised machine learning. Nat Med 9, 416–423 (2003). doi: 10.1038/nm843 CrossRefPubMedGoogle Scholar
- 37.N. Iizuka, M. Oka, H. Yamada-Okabe, M. Nishida, Y. Maeda, N. Mori, T. Takao, T. Tamesa, A. Tangoku, H. Tabuchi, K. Hamada, H. Nakayama, H. Ishitsuka, T. Miyamoto, A. Hirabayashi, S. Uchimura, Y. Hamamoto, Oligonucleotide microarray for prediction of early intrahepatic recurrence of hepatocellular carcinoma after curative resection. Lancet 361, 923–929 (2003). doi: 10.1016/S0140-6736(03)12775-4 CrossRefPubMedGoogle Scholar
- 38.Y. Hoshida, A. Villanueva, M. Kobayashi, J. Peix, D.Y. Chiang, A. Camargo, S. Gupta, J. Moore, M.J. Wrobel, J. Lerner, M. Reich, J.A. Chan, J.N. Glickman, K. Ikeda, M. Hashimoto, G. Watanabe, M.G. Daidone, S. Roayaie, M. Schwartz, S. Thung, H.B. Salvesen, S. Gabriel, V. Mazzaferro, J. Bruix, S.L. Friedman, H. Kumada, J.M. Llovet, T.R. Golub, M.E. Monaco, C.J. Creighton, P. Lee, X. Zou, M.K. Topham, D.M. Stafforini, Gene expression in fixed tissues and outcome in hepatocellular carcinoma. N Engl J Med 359, 1995–2004 (2008). doi: 10.1056/NEJMoa0804525 CrossRefPubMedPubMedCentralGoogle Scholar
- 40.X. Wu, Y. Li, J. Wang, X. Wen, M.T. Marcus, G. Daniels, D.Y. Zhang, F. Ye, L.H. Wang, X. Du, S. Adams, B. Singh, J. Zavadil, P. Lee, M.E. Monaco, Long chain fatty acyl-CoA synthetase 4 is a biomarker for and mediator of hormone resistance in human breast cancer. PLoS One 8, e77060 (2013). doi: 10.1371/journal.pone.0077060 CrossRefPubMedPubMedCentralGoogle Scholar
- 49.M. Yang, S.N. Li, K.M. Anjum, L.X. Gui, S.S. Zhu, J. Liu, J.K. Chen, Q.F. Liu, G.D. Ye, W.J. Wang, J.F. Wu, W.Y. Cai, G.B. Sun, Y.J. Liu, R.F. Liu, Z.M. Zhang, B.A. Li, A. Sanchez, A.M. Alvarez, J.M. Lopez Pedrosa, C. Roncero, M. Benito, I. Fabregat, A double-negative feedback loop between Wnt-beta-catenin signaling and HNF4alpha regulates epithelial-mesenchymal transition in hepatocellular carcinoma. J Cell Sci 126, 5692–5703 (2013). doi: 10.1242/jcs.135053 CrossRefPubMedGoogle Scholar
- 52.D. Becker, I. Sfakianakis, M. Krupp, F. Staib, A. Gerhold-Ay, A. Victor, H. Binder, M. Blettner, T. Maass, S. Thorgeirsson, P.R. Galle, A. Teufel, Genetic signatures shared in embryonic liver development and liver cancer define prognostically relevant subgroups in HCC. Mol Cancer 11, 55 (2012). doi: 10.1186/1476-4598-11-55 CrossRefPubMedPubMedCentralGoogle Scholar